These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 7535720

  • 1. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C, Sliutz G, Mustafa G, Bieglmayr C, Koelbl H, Reinthaller A, Gitsch G.
    Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
    [Abstract] [Full Text] [Related]

  • 2. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P.
    Anticancer Res; 1997 Mar; 17(3C):2329-34. PubMed ID: 9245246
    [Abstract] [Full Text] [Related]

  • 3. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC, Kao CH, Wang SJ.
    Neoplasma; 1996 Mar; 43(1):27-9. PubMed ID: 8843956
    [Abstract] [Full Text] [Related]

  • 4. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC, Shiau YC, Chang WC, Kao CH, Lin CC.
    Neoplasma; 2002 Mar; 49(6):415-7. PubMed ID: 12584591
    [Abstract] [Full Text] [Related]

  • 5. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
    Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T.
    Cancer; 1997 May 01; 79(9):1647-55. PubMed ID: 9128978
    [Abstract] [Full Text] [Related]

  • 6. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
    Wakatsuki M, Suzuki Y, Nakamoto S, Ohno T, Ishikawa H, Kiyohara H, Kiyozuka M, Shirai K, Nakayama Y, Nakano T.
    J Gastroenterol Hepatol; 2007 May 01; 22(5):715-9. PubMed ID: 17444861
    [Abstract] [Full Text] [Related]

  • 7. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, Trimbos JB.
    Gynecol Oncol; 2000 Apr 01; 77(1):164-70. PubMed ID: 10739706
    [Abstract] [Full Text] [Related]

  • 8. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A, Tana R, Cosio S, Genazzani AR.
    Crit Rev Oncol Hematol; 2008 Apr 01; 66(1):10-20. PubMed ID: 17964182
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
    Ychou M, Khemissa-Akouz F, Kramar A, Senesse P, Grenier J.
    Bull Cancer; 2001 Oct 01; 88(10):1023-7. PubMed ID: 11713038
    [Abstract] [Full Text] [Related]

  • 11. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P.
    J Exp Clin Cancer Res; 2000 Dec 01; 19(4):477-81. PubMed ID: 11277326
    [Abstract] [Full Text] [Related]

  • 12. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
    Molina R, Filella X, Augé JM, Bosch E, Torne A, Pahisa J, Lejarcegui JA, Rovirosa A, Mellado B, Ordi J, Biete A.
    Anticancer Res; 2005 Dec 01; 25(3A):1765-71. PubMed ID: 16033097
    [Abstract] [Full Text] [Related]

  • 13. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
    Forni F, Ferrandina G, Deodato F, Macchia G, Morganti AG, Smaniotto D, Luzi S, D'Agostino G, Valentini V, Cellini N, Giardina B, Scambia G.
    Int J Radiat Oncol Biol Phys; 2007 Nov 15; 69(4):1145-9. PubMed ID: 17689030
    [Abstract] [Full Text] [Related]

  • 14. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S.
    Cancer; 1996 Apr 01; 77(7):1274-7. PubMed ID: 8608502
    [Abstract] [Full Text] [Related]

  • 15. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
    Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P, Fateh-Moghadam A.
    Anticancer Res; 1996 Apr 01; 16(5B):3117-24. PubMed ID: 8920778
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection.
    Yeh JJ, Liu FY, Hsu WH, Wang JJ, Ho ST, Kao A.
    Lung; 2002 Apr 01; 180(5):273-9. PubMed ID: 12489021
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    Reesink-Peters N, van der Velden J, Ten Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, Mourits MJ, Nijman HW, Aalders JG, Hollema H, Pras E, Duk JM, van der Zee AG.
    J Clin Oncol; 2005 Mar 01; 23(7):1455-62. PubMed ID: 15735121
    [Abstract] [Full Text] [Related]

  • 20. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
    Gitsch G, Kainz C, Joura E, Fröhlich B, Bieglmayr C, Tatra G.
    Anticancer Res; 1992 Mar 01; 12(4):1247-9. PubMed ID: 1503417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.